Cetirizine
- Generic Name
- Cetirizine
- Brand Names
- Aller-tec, Aller-tec D, Quzyttir, Reactine, Wal Zyr 24 Hour Allergy, Wal Zyr D, Wal-zyr, Zerviate, Zyrtec, Zyrtec-D
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN2O3
- CAS Number
- 83881-51-0
- Unique Ingredient Identifier
- YO7261ME24
- Background
Cetirizine, also commonly known as Zyrtec, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , .
...
- Indication
Seasonal Allergic Rhinitis: Indicated for the relief of symptoms associated with seasonal allergic rhinitis caused by allergens such as ragweed, grass and tree pollens in adults and children 2 years of age and above. Symptoms treated effectively include sneezing, rhinorrhea, nasal pruritus, ocular pruritus, tearing, and redness of the eyes .
...
- Associated Conditions
- Allergy to Tree Pollen, Chronic Idiopathic Urticaria, Flu caused by Influenza, Perennial Allergic Rhinitis (PAR), Respiratory Allergy, Seasonal Allergic Rhinitis
- Associated Therapies
- -
Efficacy and Safety of Cetirizine Tablets Versus Ketotifen Dry Syrup in Children With Perennial Allergic Rhinitis
- Conditions
- First Posted Date
- 2008-03-20
- Last Posted Date
- 2009-09-04
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 149
- Registration Number
- NCT00639587
A Study To Investigate If MRI Scanning Is Effective At Seeing What Hayfever Drugs Do In Nasal Passage.
- Conditions
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2013-09-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 21
- Registration Number
- NCT00517946
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis
- Conditions
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 683
- Registration Number
- NCT00504933
Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis
- Conditions
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 239
- Registration Number
- NCT00490204
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation in Children With Allergic Rhinitis
- Conditions
- Interventions
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- Medical University of Lodz
- Target Recruit Count
- 116
- Registration Number
- NCT00488176
- Locations
- 🇵🇱
Department of Pediatrics and Allergy, Medical University of Lodz Lodz, Poland, Lodz, Poland
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
- Conditions
- Interventions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 75
- Registration Number
- NCT00420082
- Locations
- 🇦🇹
Allergy Center Vienna West, Vienna, Austria
Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 466
- Registration Number
- NCT00375713
Study to Assess the Effect of a Combination of Cetirizine With Pseudoephedrine Versus Cetirizine Alone on Symptoms in Patients With Allergic Rhinitis
- Conditions
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2010-02-03
- Target Recruit Count
- 51
- Registration Number
- NCT00334698
- Locations
- 🇩🇪
Fraunhofer-Institute of Toxicology and Experimental Medicine, Hannover, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.